Abstract

This project is designed to prepare a GMP quality investigational alternative serotypes (chimpanzee Adeno type 3) HIV vaccine and complete the preclinical and laboratory studies needed to begin a clinical trial. The first clinical trial is a Phase I study to examine tolerability, dose, and immune response of the HIV vaccine. The hypothesis is that this vaccine will be safe for human administration and elicit immune responses to HIV. Clinical materials have been manufactured in compliance with current Good Manufacturing Practices (cGMP) and released for use in Phase I clinical trials

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Production Facilities Intramural Research (ZIB)
Project #
1ZIBAI005074-12
Application #
9361513
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
12
Fiscal Year
2016
Total Cost
Indirect Cost

  Institution

Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
Zip Code